Ocular Therapeutix, Inc.

NASDAQ:OCUL

Biotechnology

Healthcare
$5.94 -1.17%

-$0.11 today

Market cap
$1.31B
Beta
0.90
P/E (TTM)
-7.3
EPS (TTM)
-$1.30
52W Low $6.23High $16.44

Volume 3.67M

Average 3.00M

OCUL Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Ocular Therapeutix, Inc.NASDAQ: OCUL

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $1.28M rose 30.8% year over year, ahead of the +20.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 2.9% from the prior quarter. Over 3 fiscal years it compounded at +27.0% a year.

Context

  • Depreciation & amortization amounted to 8.3% of revenue in FY2025, up 2.4 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +30.8% holds above the trailing-twelve-month pace of +20.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.28M+2.9% QoQ
Last fiscal yearDec 2025
$4.32M+14.2% YoY
LTMMar 2026
$4.63M+20.3% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+30.8%——
1 year+14.2%——
3-year CAGR+27.0%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
4.32M USD
Year-over-year change
+14.2%
4-year CAGR
+15.6%

Depreciation & Amortization vs competitors

How OCUL compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +20.3% is the 3rd highest of 10, against a peer median of +3.7%.
  • Depreciation & amortization amounts to 8.9% of revenue for OCUL, versus a peer median of 19.9%.
OCUL Competitors
Depreciation & Amortization for OCUL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BLCOBausch + Lomb CorporationLTM Jun 2026$411M USD-4.2%+3.6%7.7%
GKOSGlaukos CorporationLTM Jun 2026$46.44M USD+19.7%+5.6%7.6%
HROWHarrow Health, Inc.LTM Mar 2026$19.5M USD+32.3%+88.3%7.3%
KODKodiak Sciences Inc.LTM Sep 2026$19.04M USD-28.1%+33.7%—
STAASTAAR Surgical CompanyLTM Apr 2026$8.6M USD+7.6%+24.6%3.0%
OCULOcular Therapeutix, Inc.LTM Mar 2026$4.63M USD+20.3%+27.0%8.9%
OCGNOcugen, Inc.LTM Mar 2026$2.47M USD-8.6%+70.7%55.3%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$2.45M USD+41.2%-1.9%32.1%
SGPSpyGlass Pharma, Inc. Common StockFY2025$612K USD———
OCSOculis Holding AGLTM Mar 2026CHF 422.43K CHF-7.4%+20.4%83.8%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$119.64K USD+3.7%-17.0%35.9%
Peer median (excluding OCUL) —+3.7%+20.4%19.9%

Competitors are the stored peer set for OCUL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue43.52M51.49M58.44M63.72M51.82M
Cost of Revenue4.41M4.54M5.28M5.63M6.57M
Gross Profit39.12M46.95M53.16M58.1M45.25M
Gross Margin89.9%91.2%91.0%91.2%87.3%
Research & Development50.08M53.46M61.06M127.64M197.1M
Selling, General & Admin67.07M72.15M74.49M102.24M118.3M
Operating Expenses117.15M125.61M135.54M229.88M315.39M
Depreciation & Amortization2.42M2.11M2.98M3.79M4.32M
EBITDA2.54M(61.91M)(66.42M)(176.14M)(249.78M)
EBITDA Margin5.8%-120.2%-113.6%-276.4%-482.0%
Operating Income(78.04M)(78.65M)(82.38M)(171.78M)(270.02M)
Operating Margin-179.3%-152.7%-141.0%-269.6%-521.0%
Interest Income33K798K3.98M20.28M18.36M
Interest Expense6.67M7.02M11.34M13.58M11.84M
Other Income / Expenses71.48M7.62M1.65M(21.73M)4.08M
Income Before Tax(6.55M)(71.04M)(80.74M)(193.51M)(265.94M)
Pre-Tax Margin-15.1%-138.0%-138.1%-303.7%-513.2%
Income Tax Expense00000
Net Income(6.55M)(71.04M)(80.74M)(193.51M)(265.94M)
Net Margin-15.1%-138.0%-138.1%-303.7%-513.2%
EPS (Basic)(1.05)(1.04)(1.09)(1.22)(1.42)
EPS (Diluted)(0.98)(0.97)(1.02)(1.22)(1.42)
Weighted Avg Shares76.39M76.88M79.83M158.27M187.24M
Weighted Avg Shares (Diluted)82.16M82.64M85.6M158.27M187.24M

Ocular Therapeutix, Inc.

NASDAQ:OCUL

Intrinsic Alpha fair value

Locked

Current Price

$5.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.